FDA Concludes Entire Antiepileptic Category Poses Suicidality Risk
Executive Summary
FDA is concluding from its statistical analysis of suicidality for antiepileptic drugs that the entire therapeutic category poses an increased risk of suicidal behavior or ideation. But there may be a silver lining for sponsors within the data
You may also be interested in...
Boxed Warning Too Strong For Anti-Epileptic Suicidality Signal, Cmte. Says
While advisory committee members agreed that chronically used anti-epileptic drugs show a signal for suicidality, a majority of the panelists felt a class-wide "black box" warning is too strong to convey the risk
Boxed Warning Too Strong For Anti-Epileptic Suicidality Signal, Cmte. Says
While advisory committee members agreed that chronically used anti-epileptic drugs show a signal for suicidality, a majority of the panelists felt a class-wide "black box" warning is too strong to convey the risk
Antiepileptics Show Risk Of Suicidality, May Cause Labeling Convulsions
FDA findings of an increased risk of suicidality in patients given antiepileptic drugs will likely lead to broad class labeling changes, according to a MedWatch alert issued Jan. 31